LateBreaking

Latest Posts

Practically 60% of sufferers with IgAN within the SPARTAN Examine achieved full remission when...

Market

Travere Therapeutics Presents Information Reinforcing Medical Good thing about FILSPARI ® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024...

Mezagitamab-Handled Sufferers Confirmed Fast and Sustained Will increase in Platelet Counts That Persevered 8...

Market

Takeda Presents Late-Breaking Knowledge from Section 2b Research of Mezagitamab, Demonstrating Potential to Rework Remedy of Major Immune Thrombocytopenia By Investing.com